A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease

Sponsor
Mayo Clinic (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06057909
Collaborator
National Institute on Aging (NIA) (NIH)
90
1
44.9
2

Study Details

Study Description

Brief Summary

The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Magnetic Resonance Imaging
  • Diagnostic Test: Electroencephalography
  • Diagnostic Test: Electromyography

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer Disease
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2027
Anticipated Study Completion Date :
Jun 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Lewy Body Disease Group

Subjects identified by their physician with a diagnosis of Lewy body disease will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

Diagnostic Test: Magnetic Resonance Imaging
Test that looks at the structure of the brain.
Other Names:
  • MRI
  • Diagnostic Test: Electroencephalography
    Non-invasive technique to measure brain waves
    Other Names:
  • EEG
  • Diagnostic Test: Electromyography
    Technique to evaluate muscle activity
    Other Names:
  • EMG
  • Alzheimer Disease Group

    Subjects identified by their physician with a diagnosis of Alzheimer will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

    Diagnostic Test: Magnetic Resonance Imaging
    Test that looks at the structure of the brain.
    Other Names:
  • MRI
  • Diagnostic Test: Electroencephalography
    Non-invasive technique to measure brain waves
    Other Names:
  • EEG
  • Diagnostic Test: Electromyography
    Technique to evaluate muscle activity
    Other Names:
  • EMG
  • Healthy Control Group

    Subjects identified as a health individual will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

    Diagnostic Test: Magnetic Resonance Imaging
    Test that looks at the structure of the brain.
    Other Names:
  • MRI
  • Diagnostic Test: Electroencephalography
    Non-invasive technique to measure brain waves
    Other Names:
  • EEG
  • Diagnostic Test: Electromyography
    Technique to evaluate muscle activity
    Other Names:
  • EMG
  • Outcome Measures

    Primary Outcome Measures

    1. Diffusion-weighted MRI (dMRI) [Baseline]

      Measures diffusion of water molecules and cellular-level constraints

    2. Electroencephalography (EEG) [Baseline]

      Measures brain-wave activity

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 95 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Use English as their primary language.

    • Be willing to undergo health and cognitive assessments, as well as brain MRI and EEG study.

    • Will be encouraged to have an available study partner (also called a "co-participant") who is familiar with the participant's daily functioning.

    • This study will be limited to healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.

    • All individuals must be capable of providing informed consent and complying with the trial procedures. Realizing the challenge of obtaining informed consent from cognitively impaired individuals, time is specifically scheduled to foster an informative, supportive interview with the participant and caregiver/legal guardian (typically a spouse or child according to Arizona law and IRB guidelines).

    • Ongoing participation will be maintained by strict adherence to inclusion/exclusion criteria, clinical appropriateness (as determined by participant's physician and proxy/family), as well as by expressed wishes of family members/caregivers/proxy discussed at each study visit (as appropriate).

    • All participants will receive copies of the signed ICFs (including signatures of those obtaining consent).

    • All participants have the right to withdraw from the study at any time.

    Exclusion Criteria:
    • Individuals will be excluded if they have significant sensory (visual and hearing) deficits or major medical or psychiatric illnesses which would limit participation.

    • Participants will also be excluded if they have history of other major neurologic disorders including stroke, epilepsy, meningitis/encephalitis, metabolic or toxic encephalopathy, penetrating or severe closed head injury, brain tumor/other structural lesion, other primary movement disorders (such as essential tremor, dystonia, chorea, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).

    • In addition, as necessitated by the risks of Magnetic Resonance Imaging (MRI), patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator including deep brain stimulation), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain), are not eligible for participation in the MRI portion of the study. Individuals who experience claustrophobic anxiety will also be excluded from participation.

    • Women who are or might be pregnant and nursing mothers are not eligible.

    • If the subject is a woman of childbearing potential, due to unknown risks to the fetus, they must have a pregnancy test. Individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, or history of eye injury involving metal, will also be excluded unless they have had prior documented radiological clearance for MRI.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic Arizona Scottsdale Arizona United States 85268

    Sponsors and Collaborators

    • Mayo Clinic
    • National Institute on Aging (NIA)

    Investigators

    • Principal Investigator: Shannon Chiu, MD, Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Shannon Y. Chiu, Principal Investigator, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT06057909
    Other Study ID Numbers:
    • 23-007061
    • K23AG073525
    First Posted:
    Sep 28, 2023
    Last Update Posted:
    Sep 28, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 28, 2023